Content about FluMist

LONDON — Lingering fears of pandemic flu in the United States and a spike in flu activity will help to keep vaccination levels high, according to a new report.

GlobalData, a British market research firm, released a report Monday showing that seasonal influenza vaccine demand will increase from 2012's estimated 142 million to 158 million in 2022.

LONDON — The Food and Drug Administration has approved a new four-strain flu vaccine made by GlaxoSmithKline, the drug maker said.

GSK announced the approval of its Fluarix Quadrivalent (influenza virus vaccine) for children and adults against seasonal influenza subtypes A and B. The company said the vaccine was the first for intramuscular injection that protects against four strains of the virus.

 ATLANTA — The Centers for Disease Control and Prevention on Friday reported that the national incidence of influenza-like illness dropped below the national baseline of 2.2% to 1.9% and is lower than reported during the previous week. "This fluctuation may be attributed in part to a reduced number of routine health visits during the Thanksgiving holidays, as has been observed in previous seasons," the agency speculated. 

WOONSOCKET, R.I. — CVS/pharmacy and MinuteClinic are reminding families during National Influenza Vaccination Week about the importance of receiving their flu vaccinations, and are partnering with the Centers for Disease Control and Prevention and the NFL Retired Players Association to increase awareness about the benefits of annual flu vaccination.

SILVER SPRING, Md. — The Food and Drug Administration on Wednesday announced the approval of Novartis' Flucelvax, the first seasonal influenza vaccine licensed in the United States produced using cultured animal cells, instead of fertilized chicken eggs. Flucelvax is approved to prevent seasonal influenza in people ages 18 years and older.

SWIFTWATER, Pa. — Sanofi Pasteur announced Monday the presentation of three clinical trials of an experimental influenza vaccine.

WOONSOCKET, R.I. — More than half of consumers say they do not plan to get a flu shot this season, according to a recent survey conducted by CVS/pharmacy.

Flu vaccinations have received a lot of attention lately, and that’s no surprise, considering the Centers for Disease Control and Prevention’s recommendation that everyone ages 6 months and older get yearly vaccinations, not to mention the H1N1 pandemic flu scare.

Beyond the most obvious impetus for providing vaccines at the retail pharmacy level — it protects the public’s health by providing a more convenient option than making an appointment with the doctor — it also might help save money for employers.


A study recently published in the journal Cost Effectiveness and Resource Allocation found that when more vaccinations are administered in an alternate setting, such as a pharmacy, employers realize a greater cost benefit. 


NEW YORK — For the first time in a decade, sales of vaccines declined, Kalorama Information noted in a report released Thursday. A weak flu season last year was one factor that led to a 30% decline in the market to $19.8 billion in 2011, down from $24.1 billion in 2010. However, Kalorama projects that the world vaccines market will rebound — increasing at a compound annual rate of 8.9% during 2011-2016.

 SWIFTWATER, Pa. — Sanofi Pasteur is bringing its Fluzone Intradermal Vaccine Coop de Quill VacciNation Tour to Seattle Monday as part of its cross-country efforts to raise awareness about the seriousness of influenza and the various vaccine options that are available for adults 18 through 64 years old this flu season.

In an effort to help improve flu immunization rates, Sanofi Pasteur's Fluzone Intradermal Vaccine Coop de Quill VacciNation Tour will visit the Kirkland Walgreens for a flu clinic event. 

LONDON — A study recently published in the Cost Effectiveness and Resource Allocation journal found that when more vaccinations are administered in an alternate setting, such as a pharmacy, employers realize a greater cost benefit.